Efficient Hit-Finding Approaches for Histone Methyltransferases: The Key Parameters

被引:2
作者
Ahrens, Thomas [1 ]
Bergner, Andreas [1 ]
Sheppard, David
Hafenbradl, Doris [1 ]
机构
[1] BioFocus, CH-4123 Allschwil, Switzerland
关键词
epigenetics; HMT; virtual screening; G9a; EHMT2; ACCURATE DOCKING; SCORING FUNCTION; G9A; PROTEIN; METHYLATION; INHIBITORS; STRATEGIES; DISCOVERY; GLIDE;
D O I
10.1177/1087057111422823
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
For many novel epigenetics targets the chemical ligand space and structural information were limited until recently and are still largely unknown for some targets. Hit-finding campaigns are therefore dependent on large and chemically diverse libraries. In the specific case of the histone methyltransferase G9a, the authors have been able to apply an efficient process of intelligent selection of compounds for primary screening, rather than screening the full diverse deck of 900 000 compounds to identify hit compounds. A number of different virtual screening methods have been applied for the compound selection, and the results have been analyzed in the context of their individual success rates. For the primary screening of 2112 compounds, a FlashPlate assay format and full-length histone H3.1 substrate were employed. Validation of hit compounds was performed using the orthogonal fluorescence lifetime technology. Rated by purity and IC50 value, 18 compounds (0.9% of compound screening deck) were finally considered validated primary G9a hits. The hit-finding approach has led to novel chemotypes being identified, which can facilitate hit-to-lead projects. This study demonstrates the power of virtual screening technologies for novel, therapeutically relevant epigenetics protein targets.
引用
收藏
页码:85 / 98
页数:14
相关论文
共 75 条
  • [1] N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1)
    Allan, Martin
    Manku, Sukhdev
    Therrien, Eric
    Nguyen, Natalie
    Styhler, Sylvia
    Robert, Marie-France
    Goulet, Anne-Christine
    Petschner, Andrea J.
    Rahil, Gabi
    MacLeod, A. Robert
    Deziel, Robert
    Besterman, Jeffrey M.
    Nguyen, Hannah
    Wahhab, Amal
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (04) : 1218 - 1223
  • [2] The properties of known drugs .1. Molecular frameworks
    Bemis, GW
    Murcko, MA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (15) : 2887 - 2893
  • [3] Bergner A, 2001, BIOPOLYMERS, V61, P99, DOI 10.1002/1097-0282(2001/2002)61:2<99::AID-BIP10075>3.0.CO
  • [4] 2-8
  • [5] BERGNER A, 2011, SBS C 2011
  • [6] The Protein Data Bank
    Berman, HM
    Westbrook, J
    Feng, Z
    Gilliland, G
    Bhat, TN
    Weissig, H
    Shindyalov, IN
    Bourne, PE
    [J]. NUCLEIC ACIDS RESEARCH, 2000, 28 (01) : 235 - 242
  • [7] Epigenetic therapies for non-oncology indications
    Best, Jonathan D.
    Carey, Nessa
    [J]. DRUG DISCOVERY TODAY, 2010, 15 (23-24) : 1008 - 1014
  • [8] Use of Reduced Graphs To Encode Bioisosterism for Similarity-Based Virtual Screening
    Birchall, Kristian
    Gillet, Valerie J.
    Willett, Peter
    Ducrot, Pierre
    Luttmann, Claude
    [J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2009, 49 (06) : 1330 - 1346
  • [9] Functional role of G9a-induced histone methylation in small heterodimer partner-mediated transcriptional repression
    Boulias, K
    Talianidis, I
    [J]. NUCLEIC ACIDS RESEARCH, 2004, 32 (20) : 6096 - 6103
  • [10] H3K9 Histone Methyltransferase G9a Promotes Lung Cancer Invasion and Metastasis by Silencing the Cell Adhesion Molecule Ep-CAM
    Chen, Min-Wei
    Hua, Kuo-Tai
    Kao, Hsin-Jung
    Chi, Chia-Chun
    Wei, Lin-Hung
    Johansson, Gunnar
    Shiah, Shine-Gwo
    Chen, Pai-Sheng
    Jeng, Yung-Ming
    Cheng, Tsu-Yao
    Lai, Tsung-Ching
    Chang, Jeng-Shou
    Jan, Yi-Hua
    Chien, Ming-Hsien
    Yang, Chih-Jen
    Huang, Ming-Shyan
    Hsiao, Michael
    Kuo, Min-Liang
    [J]. CANCER RESEARCH, 2010, 70 (20) : 7830 - 7840